Compare Biogen Inc (BIIB) vs Vistra Corp (VST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Vistra Corp — how do they compare? Biogen Inc trades at $191.88 (market cap $28.34B), while Vistra Corp trades at $159.7 (market cap $53.42B). The key difference: Vistra Corp is the larger of the two by market cap, and Vistra Corp pays a 0.58% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | VST | |
|---|---|---|
Market Cap | $28.34B | $53.42B |
Sector | Health | Technology |
52-Week High | $216.63 | $217.92 |
52-Week Low | $122.68 | $134.71 |
Enterprise Value | $30.62B | $75.17B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $209.03, up 4.96% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, and the company maintains solid profitability with a 75.49% gross margin. Key developments include FDA approval for a subcutaneous starter dose of Leqembi and promising Phase 2 data for its Alzheimer's drug diranersen, driving positive sentiment.
The outlook is positive, with a consensus price target of $230.18 suggesting upside. Investment opportunities lie in Alzheimer's pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Revenue stability and cost management support fundamentals, though regulatory hurdles remain a watchpoint.
Vistra Corp. (VST) trades at $158.12, down 0.47% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong Q1 2026 earnings beating estimates, with revenue growth from $17.74B in 2025 to $19.4B projected for 2026. Net income margin improved to 11.52%, supported by robust cash flow from operations of $4.07B. Recent news highlights Vistra's positioning in the AI power demand surge and long-term power purchase agreements with major tech firms.
Outlook remains positive with a consensus price target of $230.50, implying significant upside. Key opportunities include exposure to growing electricity demand and strategic renewables focus. Risks involve power-price volatility, high debt levels, and execution of growth projects. Analyst sentiment is strongly bullish with 91% buy ratings, though investors should monitor Q2 2026 earnings due August 7 for confirmation of growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Vistra Corp
Vistra is a leading integrated retail electricity and power generation company that serves as a critical infrastructure provider for the digital economy. It operates a diversified portfolio of zero-carbon nuclear and renewable assets alongside a massive, flexible natural gas fleet, positioning it as an indispensable partner for energy-intensive AI data centers and industrial electrification.
Read more on VST →
